KROS · XBRL financial data

Keros Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KROS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue	—	—	—	—	0	243,864
Revenue from contracts with customers	0	20,100	0	151	3,550	244,061
Research and development	33,860	55,143	87,265	135,258	173,629	129,643
General and administrative	12,797	21,330	27,525	34,834	40,754	46,849
Total operating expenses	46,657	76,473	114,790	170,092	214,383	176,492
Operating income (loss)	(46,657)	(56,373)	(114,790)	(169,941)	(210,833)	67,569
Interest expense	6	4	1	0	0	—
Other income (expense)	160	(356)	3,031	(206)	(954)	(539)
Income tax expense (benefit)	(172)	2,011	0	0	300	4,883
Net income (loss)	(45,361)	(58,744)	(104,679)	(152,992)	(187,353)	87,014
Earnings per share, basic USD per share	(2.93)	(2.52)	(4.15)	(5.20)	(5.00)	2.34
Earnings per share, diluted USD per share	(2.93)	(2.52)	(4.15)	(5.20)	(5.00)	2.30
Weighted average shares, basic thousands of shares	15,506	23,334	25,241	29,447	37,438	37,221
Weighted average shares, diluted thousands of shares	15,506	23,334	25,241	29,447	37,438	37,859

† Share count changed about 1/2 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (KROS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	265,876	230,042	279,048	331,147	559,931	287,415
Accounts receivable	0	18,000	0	143	2,742	3,567
Prepaid and other current assets	1,850	3,398	6,719	16,003	26,220	22,202
Total current assets	267,726	251,440	285,767	347,293	588,893	315,434
Property and equipment, net	724	1,335	2,021	4,134	4,237	4,297
Right-of-use asset	878	1,067	15,548	15,334	19,251	16,841
Total assets	269,443	255,251	306,781	370,025	615,886	338,021
Accounts payable	2,149	3,645	3,339	5,450	4,602	1,967
Accrued liabilities	4,612	7,339	12,753	17,918	20,870	16,039
Total current liabilities	7,184	11,846	16,547	24,373	27,450	20,414
Lease liability, non-current	476	231	12,811	13,439	16,883	14,475
Total liabilities	7,722	12,077	29,358	37,812	44,333	34,889
Accumulated deficit	(65,011)	(123,755)	(228,434)	(381,426)	(568,779)	(481,765)
Total stockholders' equity	261,721	243,174	277,423	332,213	571,553	303,132
Total liabilities and equity	269,443	255,251	306,781	370,025	615,886	338,021
Common shares outstanding (cover page) thousands of shares	23,271	24,000	28,536	35,983	40,562	19,718

† Share count changed about 1/2 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (KROS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(45,361)	(58,744)	(104,679)	(152,992)	(187,353)	87,014
Stock-based compensation	4,097	11,722	18,682	28,763	34,872	28,696
Net cash from operating activities	(36,894)	(62,148)	(70,062)	(124,508)	(160,869)	107,505
Purchases of property and equipment	294	1,024	1,241	2,464	1,931	1,551
Net cash from investing activities	(294)	(1,024)	(1,241)	(2,464)	(1,931)	(1,551)
Proceeds from issuing common stock	140,530	—	—	—	—	—
Share repurchases	—	—	—	—	0	375,000
Net cash from financing activities	296,044	28,550	120,309	178,956	391,821	(378,470)
Net change in cash	258,856	(34,622)	49,006	51,984	229,021	(272,516)

† Share count changed about 1/2 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Keros Therapeutics	257,606	0	(20,421)*	19.8M	12.6 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122,148	37,756	10,047*	59.5M	—	Q3 FY26 10-QSep 30, 2026
Theravance Biopharma	219,766	20,731	(6,965)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
aTYR PHARMA	16,160	not reported	(9,351)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88,000	500	(10,400)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Arbutus Biopharma	19,171	1,014	(6,018)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
CytoDyn	16,359	not reported	(7,726)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026
Myriad Genetics	115,200	190,700	(8,300)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70,242	20,874	(62,549)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.